Biosimilars

• Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases
• Biosimilars – What IBD Patients Should Know
• Biosimilar Patient and Prescriber Outreach Materials
• Biosimilar Development, Review, and Approval
• Biosimilars Basics infographic for Patients
• What is a Biosimilar?
• Prescribing Biosimilar Products
• Biosimilar Development Process

Cirrhosis

• How Do Patients With Cirrhosis and Their Caregivers Learn About and Manage Their Health? A Review and Qualitative Study
• Cirrhosis
• Hepatic Encephalopathy

Eosinophilic Esophagitis (EoE)

• Diagnosis and management of eosinophilic esophagitis
• AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis
• Disease Burden and Unmet Need in Eosinophilic Esophagitis
• Biologics in Eosinophilic Gastrointestinal Diseases
• Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis
• Treatment of Eosinophilic Esophagitis: Clinical Decision Support Tool

Hepatitis C Virus (HCV)

• AGA Hepatitis C Virus FAQs
• AGA GI Patient Center: Hepatitis C (HCV)
• Direct-Acting Antivirals: Side Effects Management Handouts
• CDC Hepatitis C Resource Center
• U.S. Department of Veterans Affairs: Hepatitis C Resources for Healthcare Professionals and Patients
• Direct-Acting Antivirals: Side Effects Management Handouts
• Hepatitis C Guidance 2019 Update: AASLD‐IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Hepatitis B Virus (HBV)

• CDC Patient Education Center: Hepatitis B Virus
• CDC Testing Asian Americans and Pacific Islanders for Hepatitis
• Q&A: HIV links to diminished control of HBV coinfection
• CDC Interpretation of Hepatitis B Serologic Test Results

Inflammatory Bowel Disease (IBD)

• AGA IBD Patient Resources
• Resources For Nurses & Advanced Practice Providers: Crohn’s and Colitis Foundation
• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
• Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
• Improving IBD outcomes in the era of many treatment options
• Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis
• Efficacy and safety of biologics and small molecule drugs for patients with moderate to severe ulcerative colitis: a systematic review and network meta-analysis

Crohn’s and Colitis Foundation Resources for Patients

• Crohn’s & Colitis Foundation. Free educational brochures
• Treatment Approaches in IBD: Shared Decision-Making
• Ostomy Tips and Tricks
• Living with Crohn’s Disease
• Living with Ulcerative Colitis
• CCF IBD Medication Guide
• UIcerative Colitis 101
• Crohn’s 101

Crohn’s and Colitis Foundation Resources for Clinicians:

• Inflammatory Bowel Diseases Clinical Primer and Care Pathway Tool Kit
• IBD Nurse & Advanced Practice Provider Best Practices Resource Library
• Appeal Letters

Lysosomal Acid Lipase Deficiency (LAL-D)

• Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group
• Lysosomal Acid Lipase Deficiency (LALD) – Patient Information

Non-Alcoholic Fatty Liver Disease (NAFLD)

• Review of Clinical Guidelines in the Diagnosis of Pediatric Nonalcoholic Fatty Liver Disease
• The diagnosis and management of nonalcoholic fatty liver disease: A patient‐friendly summary of the 2018 AASLD guidelines
• NAFLD: Differential Diagnosis – Summary
• NIH Genetic and Rare Diseases Information Center: Lysosomal acid lipase deficiency